In particular, this score which included PNPLA3 and TM6SF2 genotypes, IR, diabetes, hepatic enzymes and C-reactive protein and it was able to detect NASH with an AUROC of 0.835 (95% CI, 0.776–0.895) and of 0.809 (95% CI, 0.757–0.861) in NAFLD patients with and without diabetes, respectively. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.